MILESTONE

EI-001 receives US FDA clearance to start Phase II clinical trial for vitiligo

－Winner at Moderna Taiwan mRNA Innovation Awards
－Signing a Memorandum of Understanding with National Yang Ming Chiao Tung University－

Vice President Hsiao Meets with the 2024 Outstanding Biotechnology Industry Award Recipients

Company relocates to Taipei Biotechnology Park

EI-1071 enters Phase II clinical trial for Alzheimer’s disease

Elixiron wins Startup Award at the Taiwan BIO Awards

－Elixiron ’ Class 1 Innovative Drug EI-001 for the Treatment of Vitiligo Has Received Clinical Trial (IND) Approval from China’s National Medical Products Administration (NMPA).
－EI-1071 receives TFDA clearance to start Phase II clinical trial

Elixiron and NYCU Join Forces to Develop a New Immunotherapy for Head and Neck Cancer — a Novel Therapeutic Antibody Targeting Tumor-Associated Macrophages Fused with Interleukin-10 (IL-10).

Honored with the 'Emerging Star Award' at the 2nd Life Science Entrepreneurship Competition by MIT Technology Review

Granted Orphan Drug Designation for EI-001 – targeting HLH via IFN-γ

Granted Orphan Drug Designation for EI-1071 – targeting IPF via CSF-1R

Received second round of funding from Part the Cloud Grant Program — funded by Bill Gates & Alzheimer’s Association

Completed Phase 1 trial for EI-1071 — safety profile established

FDA IND clearance granted to start Phase 1 study of EI-001

EI-1071 has completed enrollment and analysis of a total of 34 participants in the U.S. SAD study and has simultaneously initiated a Phase I MAD clinical trial in Taiwan.

Elixiron Receives a $1 Million Grant from Bill Gates and the Alzheimer’s Association

－EI-1071 Wins the National Invention Gold Award
－Signed a Memorandum of Understanding with Anji Biotech Co., Ltd.

FDA IND clearance granted to start Phase 1 study of EI-1071

The exclusive rights to the development of the drug EI-1071 were transferred through technology licensing from the Development Center for Biotechnology (DCB).

Establishment of Elixiron Immunotherapeutics, Inc.